Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 0.45 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472057 | 0.93 | ADRB3 (0.45) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL4472051 | 0.93 | ADRB3 (0.45) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL6677313 | 0.90 | ADRB3 (0.45) | ADRB3BACE1SLC2A1ADRB1 | |
| SCHEMBL6241482 | 0.90 | ADRB3 (0.46) | ADRB3BACE1ADRB1ADRB2 | |
| SCHEMBL6541595 | 0.90 | ADRB3 (0.44) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL6541582 | 0.90 | ADRB3 (0.44) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL6541590 | 0.90 | ADRB3 (0.44) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL6241489 | 0.89 | ADRB3 (0.46) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL6554211 | 0.88 | BACE1 (0.40) | ADRB3BACE1SLC2A1ADRB1ADRB2 | |
| SCHEMBL4461459 | 0.88 | ADRB3 (0.61) | ADRB3BACE1ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546086-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004002939-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | WO | disclosed |